Stay updated with the latest insights from CardioVascular Global - including clinical studies, new treatment approaches, and international collaborations.
May 1, 2026
We report an ASD closure using a fully bioresorbable occluder performed at Swiss Ablation (Zurich) within the CardioVascular Global (CVG) network. The procedure was guided by transoesophageal echocardiography. This …
May 1, 2026
An international patient travelled to Zurich for closure of an atrial septal defect (ASD) using a fully bioresorbable occluder. The procedure was performed by Dr. Horst Sievert together with …
March 31, 2026
CHAMPION AF is the first large randomized trial comparing left atrial appendage (LAA) closure with DOAC therapy in patients eligible for anticoagulation. The trial met its primary endpoints — …
March 23, 2026
The CLOSURE-AF trial is the first randomized study suggesting worse outcomes of LAA closure compared to medical therapy in high-risk atrial fibrillation patients. Key points: No difference in stroke …
December 31, 2025
The CINCH registry reports 5-year real-world outcomes of indirect mitral annuloplasty in patients with functional mitral regurgitation, demonstrating sustained clinical and echocardiographic improvement with a low rate of device- …
December 12, 2025
At Cardiology Update 2025 in London, I presented an evidence-focused overview of left atrial appendage (LAA) closure for stroke prevention in atrial fibrillation. The lecture summarized established clinical evidence …
December 1, 2025
Prof. Horst Sievert participated in the 25th CardioInterv congress in Curitiba (Brazil) and contributed to the scientific program with a lecture on new evidence in left atrial appendage (LAA) …
November 25, 2025
The CREST-2 study looked at people with severe carotid artery narrowing (70% or more) who had no symptoms such as stroke or TIA. The study compared three treatment strategies: Key results after four …
November 25, 2025
The long-awaited results of the CREST-2 trials were published in The New England Journal of Medicine on November 21, 2025. These data provide important new evidence on the management of asymptomatic high-grade …
November 20, 2025
Endovascular neuromodulation is evolving rapidly, with growing evidence that sympathetic overactivity contributes to several cardiovascular and metabolic diseases. Beyond renal denervation, multiple organs — including the liver, pancreas, duodenum, …
November 20, 2025
At the 2025 VEITHsymposium in New York, Prof. Dr. Horst Sievert presented new clinical insights into the expanding field of multiorgan denervation — a novel endovascular approach that targets …
October 29, 2025
Frankfurt, Germany – October 2025 A live educational case from CVC Frankfurt was transmitted to the Transcatheter Cardiovascular Therapeutics (TCT) 2025 congress, illustrating the catheter-based closure of a residual …
October 27, 2025
Frankfurt / Tbilisi – October 2025 CardioVascular Global has established long-term collaborations with several leading cardiovascular centres in Tbilisi, Georgia, serving as an international platform for first-in-human and early-feasibility …
October 27, 2025
Frankfurt / Tbilisi – October 2025 Patients suffering from both type 2 diabetes and high blood pressure may soon benefit from a new catheter-based treatment that acts on two …
October 27, 2025
San Francisco – October 27, 2025 Groundbreaking clinical experience with multi-organ denervation (targeting both hepatic and renal arteries) was presented at Transcatheter Cardiovascular Therapeutics (TCT) 2025. The presentation highlighted …
